COMP <GO>
BDX vs JNJ // ALTMAN Z-SCORE & DEBT/EQUITY
Becton Dickinson and Company (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BDX 4
— JNJ 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: JNJ
LAST: $197.88 (-0.23%) • MKT CAP: $54.03B
balance-sheet
2.22
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
balance-sheet
5.59
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BDX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BDX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.40% | 67.90% | -22.50 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.90% | 25.50% | -20.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.8x | 18.5x | +3.30 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 2.97% | -0.84 | JNJ | /fcf-yield <GO> |
| Operating Margin | 11.80% | 34.70% | -22.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 28.50% | -20.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 8.20% | 6.00% | +2.20 | BDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.21% | 0.00% | +2.21 | BDX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.22 | 5.59 | -3.37 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | BDX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.0 | 60.4 | +3.66 | BDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.08 | -0.02 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.9x | 23.0x | +6.90 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.03B | $662.49B | -$608.47B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BDX REV | JNJ REV | BDX GROSS % | JNJ GROSS % | BDX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.84B | $94.19B | 45.4% | 67.9% | $1.12B | $19.70B |
| FY 2024 | $20.18B | $88.82B | 45.2% | 69.1% | $1.18B | $19.84B |
| FY 2023 | $19.37B | $85.16B | 44.0% | 44.0% | $790.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BDX // BETA 1.06
JNJ // BETA 1.08